Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide starts working in your body within days of the first injection, but noticeable changes (reduced hunger, weight loss you can measure) typically take four to eight weeks to become clear. Most people in the STEP 1 trial, published in the New England Journal of Medicine, began to see meaningful weight reduction by around weeks four to eight, with results building steadily over the following months. These are prescription-only medicines: a prescriber assesses your suitability before treatment starts, and the pace of your progress is something to review with them.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common source of disappointment with semaglutide is expecting the effect to arrive quickly and evenly. It doesn't. The titration schedule for Wegovy starts at 0.25 mg precisely because the first priority is tolerability, not weight loss. At that dose, many people feel very little change in appetite, and the scales may barely move. That is not a sign the medicine isn't working. It's the design.
GLP-1 medicines work by slowing gastric emptying, reducing appetite signals and improving the hormonal response to food. Those effects accumulate. The body isn't a light switch. By the time most patients reach 1 mg, usually around week nine, appetite suppression becomes noticeably stronger. By the time they reach the 1.7 mg and then 2.4 mg maintenance doses, the clinical effect is more substantial. Expecting the 0.25 mg starter pen to deliver the results of the 2.4 mg maintenance dose is like expecting a single rehearsal to equal opening night. The NHS semaglutide patient page is clear that this slow build is intentional and normal.
If you're reading timelines on forums and comparing them to your own first few weeks, bear in mind that the posts getting the most engagement tend to be the outliers, the very fast responders and the people who struggled. Neither tells you what your own response will look like. Give the titration schedule time to do its job.
Weeks one to four are generally about settling in. The most frequently reported experiences are mild nausea after the injection, a slight reduction in appetite and the odd moment of feeling full sooner than usual at a meal. Some people notice nothing much at all. Both are within the range of normal. It helps to keep your pen in a consistent place (a fridge shelf you actually open, rather than tucked at the back) so weekly injections become part of a routine rather than something to hunt for.
Weeks five to twelve typically bring the first visible changes for most people, especially once the dose increases to 0.5 mg and then 1 mg. Appetite shifts become more reliable: meals feel satisfying with smaller portions, and cravings for high-calorie foods often ease. The scales may start showing a 1–2 kg change per month at this stage, though individual variation is wide. People who want a more detailed breakdown of early changes can find it on our semaglutide: how long it takes to work page.
Beyond twelve weeks, and through to the 1.7 mg and 2.4 mg doses, weight loss tends to accelerate. The STEP 1 trial reported an average reduction of around 15% of starting body weight over 68 weeks, but that is an average, plotted across many months of steady progress, not a number reached quickly. For those curious about how long Wegovy takes to kick in and whether that matches their own experience so far, the picture over a full year is more informative than any single month.
Several factors affect how quickly semaglutide's effect becomes apparent. Starting weight matters: someone with a higher BMI may lose a greater absolute number of kilograms before reaching the same percentage as someone closer to the threshold. Dietary patterns play a role too. The medicine reduces appetite; it doesn't override the effect of consistently high-calorie intake entirely. Physical activity, sleep, and stress levels all interact with appetite regulation, and GLP-1 medicines work within that wider system.
Missed injections reset momentum. Semaglutide has a half-life of roughly a week, so a missed dose doesn't immediately undo progress, but two or three missed injections over a month will blunt the steady-state effect. What counts as a missed dose and what to do about it is covered in the Patient Information Leaflet and is worth discussing with your prescriber rather than guessing. Our results timeline page goes into more detail on what shapes the speed of response.
It is also worth knowing that for some people the appetite effect arrives before any measurable weight change appears. Feeling less driven to snack, finishing a meal with food still on the plate, or thinking about food less often are all signs the medicine is active, and our page on how fast semaglutide kicks in explains why these early signals can appear before the scales move. If you are still uncertain whether semaglutide is right for you, or want to understand the broader options, the weight-loss treatment overview covers the full landscape.
If you have reached 1 mg and notice no reduction in appetite after a full month at that dose, that is worth raising with your prescriber. It is relatively uncommon, but some people do respond more slowly, and a clinical review can help identify whether the issue is the dose, an interaction, a lifestyle factor, or simply a need for more time. The guidance from NICE (TA875) suggests considering whether to continue treatment if less than 5% weight loss has occurred after six months on the maintenance dose. That is a clinical decision, not a self-help one.
At nume, every repeat prescription involves a genuine clinical review of your progress. If results are slower than expected, that conversation happens before your next pen is dispensed. Our clinical team can also help you understand whether a dose adjustment or a different approach to the lifestyle elements alongside treatment might make a difference. A broader look at how semaglutide's onset compares across different patient situations may also be useful reading. If you'd like to discuss your own circumstances, start a free consultation and a prescriber will review your case the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.